Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

NCT01397591 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Study closed by PI due to lower than expected accrual.

Conditions

Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions

BIOLOGICAL: Ofatumumab
DRUG: Bortezomib

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]